Drug Discovery

Lead Optimization

Bruker’s product suite delivers high quality, data-rich information to make the rational decisions in an efficient lead optimization process.

Overview

Once leads have been identified successfully, lead optimization starts to bring potent and safe drug candidates into the preclinical phase. Relevant aspects like affinity, selectivity, mode of action, synthesizability and ADMET-properties are typically improved in a multiple design-make-test-analyze (DMTA)-cycles. Bruker’s solutions provide fast, high-quality responses to ensure a high iterative pace in the DMTA-cycles required for the shortest possible time-to-market.

Picture provided by Maximilian Benz

A crucial element for any lead optimization project is the development of easily synthesizable compounds and analogs thereof. Novel synthetic technologies like microbatch synthesis allow to easily cover a broad chemical space by combinatorial synthesis but create the demand for the fast analysis of millions of compounds at volumes of a few nl only. Bruker’s rapifleX MPP  perfectly addresses this need and screens at highest pace to ensure rapid reaction control and surveillance of the chemical reactivity landscape. More detailed chemical information regarding structure, isomerization and reaction control based on larger volumes can easily be assessed by NMR , X-ray diffraction (XRD), and with the timsTOF Pro MS. Single-crystal X-ray diffraction (SC-XRD) (Link5) delivers a detailed picture of the 3D connectivity and arrangement of the atoms in the organic molecule.

A key element in lead optimization is to establish a structure-activity relationship in order to develop more potent ligands. X-ray methods, such as small angle X-ray scattering (SAXS) and single-crystal X-ray diffraction  deliver information on the structure of the protein-ligand complex, thus providing insights into spatial orientation of the ligand which is essential to rationally design more selective or potent ligands. Perfectly complementary for smaller proteins, NMR gives structural information about binding and dynamics in physiological conditions.  

Modern lead optimization requires details on temporal stability of a protein-analyte complex as early as possible. This information can be derived from the kinetic constants, like dissociation rate constants. Surface Plasmon Resonance (SPR) is highly suited at this stage as the real-time, label-free analysis of the kinetics offers direct insights beyond affinities or IC50. Moreover, the high flexibility of SPR Bruker systems allows to simultaneously investigate the binding of lead structures to up to 31 target proteins offering insights into specificity and selectivity.
Additionally, SPR allows to investigate the enthalpic and entropic contribution, key characteristics in lead optimization processes. The influence of co-factors and medium conditions such as tissue-specific pH on a protein-ligand interaction can further be analyzed by SPR.
 

Bruker’s mass spectrometry portfolio offers an additional layer of insight relevant during lead optimization. The timsTOF Pro makes use of the Parallel Accumulation Serial Fragmentation (PASEF) acquisition method, thus offering highly reliable, sensitive and fast insights into proteomics for in vitro mode of action studies. Furthermore, native MS-conditions allow to investigate protein-ligand complexes in orthogonal fashion, additionally providing information on stoichiometry besides affinities, selectivity and binding modes.

Eventually, lead optimization is also driven by improvements of ADMET-properties. Bruker’s SC-XRD, NMR, SPR and MS solutions are perfectly suited for the investigation all the way from binding assessment with plasma proteins (e.g. for increase of half-life) and metabolite analysis to distribution and toxicology studies. Most recently, our MALDI-imagining has turned out to be especially powerful studying the toxicology profile of compounds. Bruker’s magnetic resonance MS systems deliver a market-leading resolution of > 290’000 mass resolutions at m/z 400, thus enabling a comprehensive mapping of a compound.

Interesting lead compounds with optimized properties are likely to be tested in in vivo studies using both transgenic and disease models at the later stages of lead optimization. Conventionally, small rodents are used and often require ‘snap shot’ investigations where single time point experiments are carried out on excised tissue. However, Bruker’s preclinical imaging systems such as the BioSpec MRI and Skyscan micro CT can provide precise events during the disease that may be pertinent to the particular efficacy of the molecule. Bruker’s preclinical platform provides the ability to measure quantitatively and precisely anatomical, functional, metabolic and cellular mechanisms. The high data quality is ensured by longitudinal experiments where live results can influence the decision making much earlier compared to ex vivo tissue assessments. In addition, temporal in vivo biomarkers assessment within animal not only reduces total numbers of animals used but provides information on mechanisms in the intact fully functioning organ/tissue.  

Related Products

Related Products

D8 VENTURE

D8 VENTURE - 单晶 XRD 质量和多功能性标准
D8 发现

D8 DISCOVER系列

D8 DISCOVER系列是极佳的多功能X射线衍射仪平台,可为您提供业内领先的技术组件,旨在帮助您对从粉末、多晶材料到外延多层薄膜的各种材料进行结构表征。

NMR波谱仪

核磁共振波谱(NMR)是一种理想的分析技术,它可以对分子结构、动态过程和化学反应进行非侵入性、非破坏性且定量的分析研究。
rapifleX® MALDI PharmaPulse®

rapifleX® MALDI PharmaPulse®

rapifleX® MALDI PharmaPulse® 将高通量与高性能质谱仪的特异性相结合,并由专用于药物发现工作流程的新定制软件套件驱动。
timsTOF Pro

timsTOF Pro

由 PASEF® 技术支持的 timsTOF Pro 质谱仪树立了 4D-蛋白质组学的新标准,在扫描速度方面实现了革命性的改进,提高了特异性和高灵敏度。
scimaX®

scimaX®

scimaX® 采用 2xR MRMS 技术,使难以实现的目标触手可及。
纳米之星

NANOSTAR

NANOSTAR是分析1nm到125nm左右的本体或表面纳米结构的理想工具。其无与伦比的模块化设计可以让用户在SAXS、GISAXS和Nanography等各种测试方法之间随意切换。
SPR-32 Pro

Sierra SPR-32 Pro

From initial screening to detailed kinetic characterization and thermodynamics measurements, Sierra SPR-32 Pro enables high-throughput SPR analysis of molecular interactions.

BioSpec 3T

在3特斯拉的转化场中,BioSpec 3T在一个紧凑的、易于使用的场地中扩展了多用途、临床前MRI和MRS系统的范围。

SKYSCAN 1272

高分辨率台式micro-CT,具有振动隔离、CCD 检测器和微定位样品台

生命科学micro-CT

微型计算机断层扫描是一种三维 X 射线成像,其采用的方法与医院CT扫描相同,但标尺很小,分辨率大幅提高。微型计算机断层扫描是真正的三维显微术,利用此技术,细微的物体内部结构也能精确成像。

网络研讨会

支持

Labscape

Service & Life Cycle Support for Magnetic Resonance and Preclinical Imaging

Bruker’s commitment to provide customers with unparalleled help throughout the buying cycle, from initial inquiry to evaluation, installation, and the lifetime of the instrument is now characterized by the LabScape service concept.

LabScape Maintenance Agreements, On-Site On-Demand and Enhance Your Lab are designed to offer a new approach to maintenance and service for the modern laboratory